和黄医药(00013)今日盘中大涨5%,引起了市场的广泛关注。
近日,和黄医药就出售其旗下上海和记医药45%股权达成协议,交易金额高达6.08亿美元。分析师指出,此举将有利于公司集中资源于核心抗癌和免疫性新药业务,同时大幅改善公司资产负债状况,前景备受看好。
市场预计,和黄医药未来将全力推进抗癌及免疫性疾病创新疗法的发现、研发及商业化,重塑公司主营业务,因此人们对公司的长远增长充满信心。股价今日大涨,反映了投资者对公司战略调整的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.